Evidence map›Paper›PMID 35381204›Full record

ArticleAmerican journal of ophthalmology2022

Risk of Elevated Intraocular Pressure With Difluprednate in Patients With Non-Infectious Uveitis.

Mehmet Yakin, Aman Kumar, Shilpa Kodati, Leslie Jones, H Nida Sen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Efficacy, effectiveness, and safety of rho-kinase inhibitors in uveitic glaucoma and ocular hypertension secondary to uveitis: a systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Pooled it
  2. Article
  3. Article
  4. Ab externo open conjunctiva XENJournal of ophthalmic inflammation and infection · 2025
    Article
  5. Review
  6. Safe Use of Corticosteroids in Non-Infectious Uveitis.Journal of inflammation research · 2025
    Review
  7. Review
  8. Review
  9. Update on Diagnosis and Treatment of Uveitic Glaucoma.Journal of clinical medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Mehmet YakinFrom the National Eye Institute, National Institutes of Health, Bethesda, MD, USA (M.Y, A.K, S.K, H.N.S); University of Health Sciences, Ankara Training and Research Hospital, Ophthalmology Department, Ankara, Turkey (M.Y).
Aman KumarFrom the National Eye Institute, National Institutes of Health, Bethesda, MD, USA (M.Y, A.K, S.K, H.N.S); Albany Medical College, Albany, NY (A.K).
Shilpa KodatiFrom the National Eye Institute, National Institutes of Health, Bethesda, MD, USA (M.Y, A.K, S.K, H.N.S).
Leslie JonesHoward University College of Medicine, Ophthalmology Department, Washington DC, USA (L.J).
H Nida SenFrom the National Eye Institute, National Institutes of Health, Bethesda, MD, USA (M.Y, A.K, S.K, H.N.S). Electronic address: senh@nei.nih.gov.
National Institutes of Health · USHoward University · US

Funding

Studies of Ocular inflammation: Translational ResearchZIAEY000556 · NEI · NATIONAL EYE INSTITUTE · PI CASPI, RACHEL R. · 2017 to 2025
$11.3M
Intramural NIH HHS Z99 EY999999
6 · The paper itself

Abstract

purposeTo evaluate the risk factors associated with clinically important intraocular pressure (IOP) elevation with topical difluprednate treatment in patients with non-infectious uveitis.

designRetrospective cohort study.

methodsFifty-four eyes of 54 patients with non-infectious uveitis treated with topical difluprednate at the current institution were included. Demographics and clinical characteristics of uveitis patients were collected. The main outcome measure was development of clinically important IOP elevation defined as IOP ≥21 mmHg and an increase of ≥10 mmHg from baseline.

resultsA clinically important IOP elevation was observed in 17 patients (31.5%). The mean time to clinically important IOP elevation was 7.4±4.8 weeks (range 3-19). Statistically significant risk factors for incident clinically important IOP elevation were being a child (adjusted hazard ratio [aHR] 7.85 [95% CI 1.48-41.56], P = .02) and concurrent use of systemic steroids (aHR 5.31 [95% CI 1.18-24.00], P = .03). Patients with concurrent systemic corticosteroids developed clinically important IOP elevation earlier than those without systemic corticosteroid (mean 5.7±3.4 [range 3-14] vs 10.4±5.7 [range 4-19] weeks, P = .05). Incident IOP ≥30 mmHg occurred in 7 patients (13.0%). All patients responded well to the cessation of difluprednate and/or use of topical antiglaucomatous agents and no eyes required glaucoma surgery.

conclusionsThis study demonstrated that clinically important IOP elevation is common in uveitis patients with topical difluprednate treatment. Children and patients with concurrent systemic corticosteroids are at substantial risk of developing clinically important IOP elevation.

Indexed as

GlaucomaUveitisChildFluprednisoloneGlucocorticoidsHumansIntraocular PressureRetrospective StudiesdifluprednateFluprednisoloneGlucocorticoids

Identifiers

PMID35381204
PMCPMC9308646
OpenAlexW4225880171

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.